Lupin Launches Silodosin Caps | CORPORATE ETHOS

Lupin Launches Silodosin Caps

By: | December 4, 2018
lupin

Dec 4: Mumbai-based pharma major Lupin Ltd on Tuesday announced the launch of its Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

According to the company, the product is the generic equivalent of Allergan’s Rapaflo. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Rapaflo had annual sales of $198.5 million in the US (IQVIA MAT September 2018).